XML 56 R39.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue Recognition (Tables)
 12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
The following table represents Evolent’s revenue disaggregated by end-market and product type (in thousands):
For the Year Ended December 31,
202320222021
Medicaid$785,053 $559,362 $421,069 
Medicare708,853 458,413 407,331 
Commercial and other469,990 334,238 79,557 
Total$1,963,896 $1,352,013 $907,957 
Performance Suite$1,214,661 $808,642 $550,959 
Specialty Technology and Services Suite296,366 51,898 42,501 
Administrative Services296,244 407,523 309,803 
Cases156,625 83,950 4,694 
Total$1,963,896 $1,352,013 $907,957 
Schedule of Contract with Customer, Asset and Liability
The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of December 31, 2023 and December 31, 2022 (in thousands):
December 31,
20232022
Short-term receivables (1)
$446,220 $246,209 
Short-term deferred revenue5,976 5,758 
Long-term deferred revenue1,173 2,533 
————————
(1)Excludes pharmacy claims receivable and premiums receivable.

Changes in deferred revenue for the year ended December 31, 2023, are as follows (in thousands):
Deferred revenue
Balance as of beginning-of-period$8,291 
Reclassification to revenue, as a result of performance obligations satisfied(5,742)
Cash received in advance of satisfaction of performance obligations4,600 
Balance as of end of period$7,149